Rallybio Sets Record Date and Finalizes Reverse Merger Terms with Avenzo
RLYB has more than doubled off its 52-week low of $3.67 on light trading volume (0.3× avg).
Summary
The latest S-4 amendment sets the shareholder vote record date and finalizes terms of the Avenzo reverse merger, including a 1-for-5.5 reverse split and issuance of approximately 35.2 million shares. Existing Rallybio stockholders will retain only 2.8% ownership of the combined company.
Key Events · M&A and Partnerships · RLYB
-
Record Date Set for Shareholder Vote
September 11, 2026 is fixed as the record date, with 5,312,584 shares outstanding and entitled to vote on the Avenzo reverse merger proposals.
-
Reverse Split Ratio Assumed at 1-for-5.5
The amendment assumes a 1-for-5.5 reverse stock split (within the approved 1-for-2 to 1-for-9 range), resulting in approximately 35,206,766 shares issued to Avenzo holders.
-
Ownership Structure Finalized
Post-merger ownership: Avenzo pre-merger holders 56.6%, concurrent financing investors 40.6%, and existing Rallybio stockholders just 2.8% of the combined company.
-
Avenzo Going Concern Warning
Avenzo reports a $324.4 million accumulated deficit as of June 30, 2026, with substantial doubt about its ability to continue as a going concern, mitigated by the $215 million concurrent financing.
Analysis · RLYB · Life Sciences
The fourth S-4 amendment locks in the mechanics of the Avenzo reverse merger: a September 11 record date with 5.3 million shares voting, an assumed 1-for-5.5 reverse split, and approximately 35.2 million shares to be issued to Avenzo holders. After the deal closes, existing Rallybio stockholders will own just 2.8% of the combined company, while Avenzo holders take 56.6% and concurrent financing investors 40.6%. The filing also confirms Avenzo's going concern warning with a $324.4 million accumulated deficit, underscoring why the $215 million concurrent financing is critical to fund operations into late 2028.
How filings like this one have moved
In the 30 days to Oct 14, 2026, 36.6% of the 951 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RLYB was trading at $16.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $89.8M. The 52-week trading range was $3.67 to $17.57. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.